We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3M to Divest Drug Delivery Business to Altaris Capital Unit
Read MoreHide Full Article
3M Company (MMM - Free Report) recently announced that it has inked an agreement with an affiliate of Altaris Capital Partners, LLC to divest considerably all of its drug delivery business. The deal, worth of about $650 million, includes cash, a 17% noncontrolling interest in the new company and an interest-bearing security. The deal is subject to customary closing conditions and regulatory approvals, and is projected to close in the first half of 2020.
Details of the Divestment Deal
3M’s drug delivery business is engaged in developing and producing pharmaceutical products, leveraging transdermal, inhalation and conventional drug delivery technologies. It’s worth noting here that the business considered for divestment has annual global sales of roughly $380 million. Meanwhile, the company will continue to operate its transdermal drug delivery components business.
As noted by 3M, about 900 employees of its drug delivery business are likely to join the new company as a result of the divestment. As a matter of fact, the deal will enable the company to emphasize on its core health care business.
On completion, the deal is likely to lead to a gain of 45 cents to 50 cents per share for 3M, The company will report its ownership interest in the drug delivery business with the help of the equity method of accounting.
Other Inorganic Moves
Some other notable inorganic activities completed by the company are the sale of its gas and flame detection business to Teledyne Technologies Inc. (TDY - Free Report) and an agreement to sell its advanced ballistic-protection business to Avon Rubber, both in August 2019. In addition, 3M divested its communication markets business in 2018 while completed the buyout of the technology business of M*Modal in February 2019. Also, it completed the acquisition of Acelity Inc and its KCI subsidiaries in October. In this regard, acquired assets and divestments had a net positive impact of 0.6% on sales in the third quarter of 2019.
3M currently carries a Zacks Rank #3 (Hold). In the past six months, the company has returned 1.1% compared with the industry’s growth of 6.3%.
Macquarie surpassed estimates twice in the trailing four quarters, the average positive earnings surprise being 5.34%.
ITT outpaced estimates in each of the preceding four quarters, the average positive earnings surprise being 7.85%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
3M to Divest Drug Delivery Business to Altaris Capital Unit
3M Company (MMM - Free Report) recently announced that it has inked an agreement with an affiliate of Altaris Capital Partners, LLC to divest considerably all of its drug delivery business. The deal, worth of about $650 million, includes cash, a 17% noncontrolling interest in the new company and an interest-bearing security. The deal is subject to customary closing conditions and regulatory approvals, and is projected to close in the first half of 2020.
Details of the Divestment Deal
3M’s drug delivery business is engaged in developing and producing pharmaceutical products, leveraging transdermal, inhalation and conventional drug delivery technologies. It’s worth noting here that the business considered for divestment has annual global sales of roughly $380 million. Meanwhile, the company will continue to operate its transdermal drug delivery components business.
As noted by 3M, about 900 employees of its drug delivery business are likely to join the new company as a result of the divestment. As a matter of fact, the deal will enable the company to emphasize on its core health care business.
On completion, the deal is likely to lead to a gain of 45 cents to 50 cents per share for 3M, The company will report its ownership interest in the drug delivery business with the help of the equity method of accounting.
Other Inorganic Moves
Some other notable inorganic activities completed by the company are the sale of its gas and flame detection business to Teledyne Technologies Inc. (TDY - Free Report) and an agreement to sell its advanced ballistic-protection business to Avon Rubber, both in August 2019. In addition, 3M divested its communication markets business in 2018 while completed the buyout of the technology business of M*Modal in February 2019. Also, it completed the acquisition of Acelity Inc and its KCI subsidiaries in October. In this regard, acquired assets and divestments had a net positive impact of 0.6% on sales in the third quarter of 2019.
3M currently carries a Zacks Rank #3 (Hold). In the past six months, the company has returned 1.1% compared with the industry’s growth of 6.3%.
Key Picks
A couple of better-ranked stocks from the same space are Macquarie Infrastructure Company and ITT Inc. (ITT - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Macquarie surpassed estimates twice in the trailing four quarters, the average positive earnings surprise being 5.34%.
ITT outpaced estimates in each of the preceding four quarters, the average positive earnings surprise being 7.85%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>